External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home JSMO 2026
Roche and Genentech at

JSMO 2026

March 26 - March 28
Yokohama, Japan / Virtual (Hybrid)
congre.co.jp/jsmo2026
We will be contributing to topics related to
Oncology
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
04:05 AM
Duration 45mins Yokohama, Japan
Krascendo 2: Phase III study of divarasib + pembrolizumab vs pembrolizumab + chemotherapy in untreated KRAS G12C+ NSCLC
Hiroaki Akamatsu
Oncology | Non-Squamous Non-Small Cell Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
05:00 AM
Duration 120mins Yokohama, Pacifico Yokohama (North & Exhibition Hall D)
SKYSCRAPER-07: Japanese subgroup analyses of a Phase 3 study of atezolizumab ± tiragolumab in unresectable ESCC after definitive chemoradiotherapy
Keisho Chin
Oncology | Esophageal Squamous Cell Carcinoma

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.